Trexquant Investment LP Pds Biotechnology Corp Transaction History

Trexquant Investment LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$4.8 - $6.4 $124,084 - $165,446	25,851 New	25,851 $130,000
Q1 2023 May 15, 2023	BUY	$5.68 - $11.99 $79,531 - $167,883	14,002 Added 58.08%	38,110 $234,000
Q4 2022 Feb 13, 2023	BUY	$3.28 - $13.2 $79,074 - $318,225	24,108 New	24,108 $318,000
Q2 2022 Aug 11, 2022	SELL	$3.05 - $6.68 $211,779 - $463,832	-69,436 Reduced 82.09%	15,151 $55,000
Q1 2022 May 13, 2022	BUY	$4.78 - $8.43 $197,036 - $347,493	41,221 Added 95.05%	84,587 $524,000
Q4 2021 Feb 14, 2022	BUY	$7.76 - $14.35 $7,604 - $14,063	980 Added 2.31%	43,366 $351,000
Q3 2021 Nov 12, 2021	BUY	$9.33 - $17.08 $395,461 - $723,952	42,386 New	42,386 $632,000

4.22M

170K

6.7K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $38.1M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.